The Beginning of the End for Merck?

"Taken together, these inaccuracies and deletions call into question the integrity of the data on adverse cardiovascular events in this article." from an editorial in today's New England Journal of Medicine commenting on a major Vioxx study reported in a previous issue of the Journal. The report apparently omitted the fact that three of the subjects died of heart attacks, which, in the Journal's view "made certain calculations and conclusions in the article incorrect".